We are proud to announce that Dr. Iurii Arian has been approved by the International Society for Sexual Medicine (ISSM) and the European Society for Sexual Medicine (ESSM) to present three prospective clinical studies at the 27th World Meeting on Sexual Medicine, taking place on February 25–28, 2026, in Porto, Portugal.
These studies evaluate advanced applications of low-intensity extracorporeal shockwave therapy (LiESWT) in the treatment of erectile dysfunction (ED) and Peyronie’s disease (PD), using the MoreNova shockwave system. Together, they represent a significant contribution to the growing body of clinical evidence supporting non-invasive, optimized treatment approaches in men’s sexual health.
Overview of the Approved Studies
The three prospective, open-label studies include a total of 150 patients and investigate different LiESWT-based treatment strategies designed to address both functional and structural aspects of male sexual dysfunction:
1. Low-Intensity Shockwave Therapy Integrated with Multimodal Treatment in Peyronie’s Disease and Erectile Dysfunction
This study evaluates the role of LiESWT as part of a multimodal therapeutic approach in patients presenting with Peyronie’s disease accompanied by erectile dysfunction. Outcomes demonstrated clinically meaningful improvements in penile curvature and plaque characteristics, alongside improvements in erectile function.
2. Condensed Sequential Multi-Zonal LiESWT for Vasculogenic Erectile Dysfunction
This study explores a condensed treatment protocol using sequential multi-zonal shockwave delivery for patients with vasculogenic ED. The results showed significant improvements in erectile function scores and measurable enhancements in penile hemodynamics, supporting the potential of protocol optimization to improve treatment efficiency and outcomes.
3. Micro-Dose Intracavernosal Alprostadil Priming Before LiESWT for Vasculogenic Erectile Dysfunction
This novel study investigates a synergistic approach combining micro-dose intracavernosal alprostadil priming prior to LiESWT. The protocol was designed to enhance tissue responsiveness and vascular outcomes, resulting in a high proportion of patients achieving clinically meaningful improvements in erectile function.
Key Clinical Outcomes
Across all three prospective studies, treatments performed with the MoreNova system demonstrated:
- Meaningful improvements in erectile function
- Significant reduction in Peyronie’s curvature and plaque
- Strong improvements in penile hemodynamics
- Zero adverse events across all 150 patients
The absence of reported adverse events across a substantial patient population underscores the strong safety profile of LiESWT when delivered using carefully designed protocols and validated technology.
Advancing Evidence-Based Men’s Health Care
These studies reflect an important shift in men’s sexual health toward data-driven, patient-centered, and non-invasive therapeutic solutions. By focusing on optimized treatment protocols, real-world clinical outcomes, and safety, this work contributes meaningful evidence to support the evolving role of LiESWT in sexual medicine.
We congratulate Dr. Iurii Arian on this important scientific achievement and are proud to support clinical partners who continue to advance the field through rigorous research and innovation.
We look forward to the presentation of these studies and the discussions they will generate at the 27th World Meeting on Sexual Medicine in Porto.